Advanced Search
Library
Clinical Study

Effect of Switching From Cigarette Smoking to the Use of Platform 1on Periodontitis Treatment Outcome

Full Title

A 6-month Randomized, Controlled, Open-label, 2-arm Parallel Group, Multicenter Study to Evaluate the Effect of Switching From Cigarette Smoking to the Use of Platform 1 in Smokers With Generalized Chronic Periodontitis on the Response to Mechanical Periodontal Treatment and Oral Health Status.


Authored by  PMI
Abstract

The purpose of this study is to demonstrate in patients with generalized chronic periodontitis that switching from cigarette smoking to using Platform 1 improves the response to periodontal therapy and the overall oral health status compared to continuing cigarette smoking.

Summary

Recruitment    Recruiting
Study Results  No Results Available
Enrollment  172 (estimated)
Study Type  Interventional  (Clinical Trial)
Other IDs  P1-OHS-01-JP









PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

Our RRPs

Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.